BioImagene Raises $26 M in Expansion Capital
CUPERTINO, Calif. (Business Wire EON/PRWEB ) August 19, 2008 --
BioImagene, the leading
provider of affordable digital pathology solutions for cancer diagnosis
and preclinical research, today announced the closing of a $26 million
series D financing round led by Burrill
& Company. Ascension
Health Ventures, National
Healthcare Services and existing investors Artiman
Ventures and ICCP
Ventures also joined the round with strong support.
Mr. Yatin Mundkur, Artiman Ventures Partner and BioImagene board member
noted “This follow-on investment reaffirms our
commitment to the BioImagene team and their innovative products, and
reinforces our belief in the enormous growth potential of digital
pathology. We are very happy to guide the company through their next
phase of future growth.”
BioImagene CEO Mohan Uttarwar commented, “This
latest infusion of capital from leading investors is a strong vote of
confidence in our team, products and strategy. Our goal is to become the
dominant player in this space by 2010. We are within range of our target
and this funding will help us scale operations to support the rapidly
increasing demand for affordable, integrated digital pathology systems. ”
Digital pathology is the process of converting entire glass microscope
slides into high-resolution, whole-slide digital images that can be
viewed, managed and analyzed with a computer instead of a microscope—along
with digital pathology management systems that help interpret the
information generated from the digitized glass slide.
Digital pathology applications utilizing digital slides are gaining
momentum as pathologists can access slide specimens and related data
from any location in the world, fostering more efficient laboratory
workflow, physician communication, education and research at a
reasonable cost.
Investor Information
For more information on Artiman Ventures, please visit www.artimanventures.com
For more information on Ascension Health Ventures, please visit www.ascensionhealthventures.org
For more information on Burrill & Company, please visit www.burrillandco.com
For more information on National Healthcare Services (NHS), please visit www.nationalhealthcareservices.com
For more information on ICCP Ventures, please visit www.iccpventurepartners.com
About BioImagene
BioImagene is a leading provider of total digital pathology solutions
for applications including clinical diagnostics and drug discovery.
BioImagene products are FDA -cleared for specific clinical applications,
and are intended for research use for other applications. www.bioimagene.com.
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1NYWduLUhvcnItSG9yci1Db3VwLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.